Sridhar Narayan, PhD, MBA
Vice President of Drug Discovery, ReviR Therapeutics
Image
| Sridhar Narayan is a scientist and entrepreneur who brings extensive experience from the life sciences industry. He’s currently a Vice President at ReviR Therapeutics where he leads the development of novel drugs that modulate RNA targets. He is intimately involved in the application of Artificial intelligence and machine learning (AI/ML) for drug discovery. Prior to ReviR, Sridhar was VP of Drug Discovery and Program Leadership at Satellos Bioscience, a company focused on muscle regeneration, which he helped launch in 2018. In 2015, he was involved in starting Appili Therapeutics where he served as Project Director and Member of the Scientific Advisory Board until 2020. Previously, Sridhar held scientific leadership positions at Navitor Pharmaceuticals, AstraZeneca and Eisai, where he led projects from early discovery through FIH studies. He has a track record of moving several compounds into clinical development and his expertise spans oncology, immunology/ inflammation, metabolic disorders, infectious diseases, CNS and rare disease. Sridhar has also consulted with biotech and VC firms on new ventures, drug discovery & development, strategy, and business development. Sridhar received his PhD from the University of Michigan and carried out postdoctoral research at the Scripps Research Institute with two-time Nobel Laureate K. Barry Sharpless. He also holds an MBA from the Yale School of Management. |